Industry News
Pharmaceutical Industry News
Sanofi has gained an FDA expansion…
Sanofi has gained an FDA expansion for its Type 1 diabetes treatment Tzield. The decision came nearly two months after an original target date under former FDA chief Marty Makary’s controversial Commissioner’s National Priority Voucher
As the United Kingdom juggles…
As the United Kingdom juggles industry concerns about the region’s waning appeal and competitiveness, Eisai is getting a lift from a production-tinged fund that the British government first unveiled in 2024.
In patients with BTK-pretreated…
In patients with BTK-pretreated chronic lymphocytic leukemia, AbbVie and Roche’s Venclexta is the drug to beat. But no companies had taken a daunting head-to-head challenge—until Eli Lilly made the leap of faith with its Jaypirca.
Scientists Race to Test Treatments as Ebola Outbreak Widens
Trials are beginning on several drugs that have shown promise in preliminary studies against the virus that is causing the current outbreak.
J&J’s MonumenTAL-3 phase 3…
J&J's MonumenTAL-3 phase 3 study of bispecific antibody Talvey and Darzalex Faspro in patients with earlier-stage multiple myeloma earned a plenary spot at the 2026 European Hematology Association annual meeting.
An independent research firm is…
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing with the FDA which could determine whether the rare disease treatment remains on the market.
The accelerated approval for Jazz…
The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer drug Zepzelca may once again be in jeopardy after another phase 3 failure.
With Measles Roaring Back, the Search for a Drug is On
As vaccination rates decline, biotech companies see a potential new market for measles drugs.
Audio is becoming an increasingly…
Audio is becoming an increasingly important area of focus in pharma marketing, and now four big drugmakers have become sponsors of a new podcast focused on Alzheimer’s disease.
Astellas CEO explained to Fierce…
Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a head-to-head psoriasis trial. RA Capital is offering China capabilities to its portfolio companies through a
There was a big uptick in the use…
There was a big uptick in the use of AI across all HHS agencies in 2025, though analysts note some use cases may “reflect new reporting requirements instead of new deployments."
As cybersecurity threats have…
As cybersecurity threats have proliferated across industries in recent years, biopharma companies have emerged as prominent targets, with intellectual property, patient data and other sensitive information at stake. Now, Novo Nordisk is the latest drug
Staring down a $6 billion patent…
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savings program anchored in its new five-year
Facing drug pricing pressure from…
Facing drug pricing pressure from the U.S., Belgium, the Netherlands, Luxembourg, Austria and Ireland stressed the need for "collaborative efforts across the Union" in a June 10 statement.
While the demand in Asia-Pacific…
While the demand in Asia-Pacific clearly exists, getting approved therapies into these markets is difficult without local support.
Johnson & Johnson has unveiled…
Johnson & Johnson has unveiled data from a pivotal phase 2/3 trial which could pave the way for a label expansion for Imaavy to become the first approved treatment for warm autoimmune hemolytic anemia.
The Crohn’s & Colitis…
The Crohn's & Colitis Foundation has tapped agency Olixir NY for its new inflammatory bowel disease public service announcement.
Why tumor-informed MRD is emerging…
Why tumor-informed MRD is emerging as a strategic lens for how oncology teams design smarter trials, interpret response earlier and navigate development risk with greater confidence.
Zandoriah® becomes CinnaGen’s…
Zandoriah® becomes CinnaGen’s first EU-authorised medicine, reflecting years of investment in infrastructure and manufacturing excellence.
Life sciences teams are sourcing…
Life sciences teams are sourcing and managing data with a hidden cost: missed patients, missed project/launch windows and incomplete decisions.